Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium

Theo G.m. van Erp, Derrek P. Hibar, Jerod M. Rasmussen, David C. Glahn, Godfrey D. Pearlson, Ole A. Andreassen, Ingrid Agartz, Lars T. Westlye, Unn K. Haukvik, Anders M. Dale, Ingrid Melle, Cecilie B. Hartberg, Oliver Gruber, Bernd Kraemer, David Zilles‐Wegner, Gary Donohoe, Sinéad Kelly, Colm McDonald, Derek W. Morris, Dara M. Cannon, Aiden Corvin, Marise W. J. Machielsen, Laura Koenders, Lieuwe de Haan, Dick J. Veltman, Theodore D. Satterthwaite, Daniel H. Wolf, Ruben C. Gur, R.e. Gur, Steven G. Potkin, Daniel H. Mathalon, Bryon A. Mueller, Adrian Preda, Fabìo Macciardi, Stefan Ehrlich, Esther Walton, Johanna Haß, Vince D. Calhoun, H. Jeremy Bockholt, Scott R. Sponheim, Jody M. Shoemaker, Neeltje E.m. van Haren, Hilleke E. Hulshoff Pol, R A Ophoff, R.s. Kahn, Roberto Roiz‐Santiáñez, Benedicto Crespo‐Facorro, Lei Wang, K I Alpert, E G Jönsson, Ralica Dimitrova, C. Bois, Heather C. Whalley, Andrew M. McIntosh, Stephen M. Lawrie, R Hashimoto, Paul M. Thompson, Jessica A. TurnerMolecular 2015 · DOI

Abstract

The profile of brain structural abnormalities in schizophrenia is still not fully understood, despite decades of research using brain scans. To validate a prospective meta-analysis approach to analyzing multicenter neuroimaging data, we analyzed brain MRI scans from 2028 schizophrenia patients and 2540 healthy controls, assessed with standardized methods at 15 centers worldwide. We identified subcortical brain volumes that differentiated patients from controls, and ranked them according to their effect sizes. Compared with healthy controls, patients with schizophrenia had smaller hippocampus (Cohen's d=-0.46), amygdala (d=-0.31), thalamus (d=-0.31), accumbens (d=-0.25) and intracranial volumes (d=-0.12), as well as larger pallidum (d=0.21) and lateral ventricle volumes (d=0.37). Putamen and pallidum volume augmentations were positively associated with duration of illness and hippocampal deficits scaled with the proportion of unmedicated patients. Worldwide cooperative analyses of brain imaging data support a profile of subcortical abnormalities in schizophrenia, which is consistent with that based on traditional meta-analytic approaches. This first ENIGMA Schizophrenia Working Group study validates that collaborative data analyses can readily be used across brain phenotypes and disorders and encourages analysis and data sharing efforts to further our understanding of severe mental illness.

Introduction

Despite decades of neuroimaging, the structural "fingerprint" of schizophrenia has remained elusive. Most previous studies suffered from small sample sizes, leading to inconsistent or even contradictory results. Furthermore, traditional "retrospective" meta-analyses—which pool results from already-published papers—are often hampered by publication bias and the "apples-to-oranges" problem of different sites using different analysis software and statistical models.

The ENIGMA consortium sought to overcome these hurdles by creating a coordinated, global framework to analyze raw data using identical methods. This approach provides the statistical power necessary to rank brain abnormalities by their effect sizes and investigate how factors like medication and illness duration influence brain structure.

Methods

The researchers employed a prospective meta-analysis approach. Instead of just reading old papers, they coordinated with 15 international research centers to run a standardized analysis pipeline on their local datasets.

  • Image Processing: All sites used FreeSurfer, an automated tool for segmenting subcortical structures (like the hippocampus, amygdala, and thalamus) from T1-weighted MRI scans.
  • Statistical Modeling: They used univariate linear regressions to compare patients and controls, adjusting for age, sex, and total intracranial volume (ICV).
  • Effect Size: Results were standardized using Cohen’s d, allowing for a direct comparison of the "magnitude" of abnormality across different brain regions.
  • Moderator Analysis: The team used meta-regression to see if variables like the age of onset, duration of illness, or the type of antipsychotic medication explained the differences in volume observed between different study sites.

Key Results

The study established a clear ranking of subcortical changes. The hippocampus showed the most robust deficit, while the lateral ventricles showed the most significant enlargement.

Ranking of subcortical volume abnormalities by effect size (Cohen's d).

The study reported several significant differences between schizophrenia patients and healthy controls (all values are Cohen’s d effect sizes):

  • Significant Volume Reductions:
    • Hippocampus ($d = -0.46$)
    • Amygdala ($d = -0.31$)
    • Thalamus ($d = -0.31$)
    • Nucleus Accumbens ($d = -0.25$)
    • Intracranial Volume ($d = -0.12$)
  • Significant Volume Increases:
    • Lateral Ventricles ($d = 0.37$)
    • Pallidum ($d = 0.21$)

No detectable differences were found for the caudate or putamen when simply comparing groups, though the putamen was linked to illness duration in later analyses.

Key Insights: Medication and Illness Duration

The findings suggest a complex interplay between the disease and its treatment. While most structures shrink in schizophrenia, the pallidum and putamen actually showed volume increases.

Moderator analysis P-values showing the influence of clinical variables on brain volumes.

These increases were positively correlated with the duration of illness and antipsychotic dosage (CPZ equivalents), suggesting they may be a side effect of medication rather than a primary feature of the disorder. Furthermore, hippocampal volume loss was most severe in cohorts with a higher proportion of unmedicated patients. This suggests that untreated psychosis may be particularly damaging to the hippocampus, or conversely, that medication might have a partially "protective" effect on this region.

Conclusion

This paper serves as a "proof of concept" for the ENIGMA consortium, proving that large-scale, decentralized collaboration can produce much more reliable neurobiological markers than isolated research efforts. While the study provides a definitive "snapshot," its cross-sectional design cannot definitively say how these brain volumes change within a single individual over time. Future work by the ENIGMA group plans to expand this work to include cortical thickness, surface area, and longitudinal mapping to further our understanding of severe mental illness.

Summary updated

Abstract

The profile of brain structural abnormalities in schizophrenia is still not fully understood, despite decades of research using brain scans. To validate a prospective meta-analysis approach to analyzing multicenter neuroimaging data, we analyzed brain MRI scans from 2028 schizophrenia patients and 2540 healthy controls, assessed with standardized methods at 15 centers worldwide. We identified subcortical brain volumes that differentiated patients from controls, and ranked them according to their effect sizes. Compared with healthy controls, patients with schizophrenia had smaller hippocampus (Cohen's d=-0.46), amygdala (d=-0.31), thalamus (d=-0.31), accumbens (d=-0.25) and intracranial volumes (d=-0.12), as well as larger pallidum (d=0.21) and lateral ventricle volumes (d=0.37). Putamen and pallidum volume augmentations were positively associated with duration of illness and hippocampal deficits scaled with the proportion of unmedicated patients. Worldwide cooperative analyses of brain imaging data support a profile of subcortical abnormalities in schizophrenia, which is consistent with that based on traditional meta-analytic approaches. This first ENIGMA Schizophrenia Working Group study validates that collaborative data analyses can readily be used across brain phenotypes and disorders and encourages analysis and data sharing efforts to further our understanding of severe mental illness.
BibTeX
@inproceedings{erp2015subcortical,
  author = {Theo G.M. van Erp and Derrek P. Hibar and Jerod M. Rasmussen and David C. Glahn and Godfrey D. Pearlson and Ole A. Andreassen and Ingrid Agartz and Lars T. Westlye and Unn K. Haukvik and Anders M. Dale and Ingrid Melle and Cecilie B. Hartberg and Oliver Gruber and Bernd Kraemer and David Zilles‐Wegner and Gary Donohoe and Sinéad Kelly and Colm McDonald and Derek W. Morris and Dara M. Cannon and Aiden Corvin and Marise W. J. Machielsen and Laura Koenders and Lieuwe de Haan and Dick J. Veltman and Theodore D. Satterthwaite and Daniel H. Wolf and Ruben C. Gur and R.E. Gur and Steven G. Potkin and Daniel H. Mathalon and Bryon A. Mueller and Adrian Preda and Fabìo Macciardi and Stefan Ehrlich and Esther Walton and Johanna Haß and Vince D. Calhoun and H. Jeremy Bockholt and Scott R. Sponheim and Jody M. Shoemaker and Neeltje E.M. van Haren and Hilleke E. Hulshoff Pol and Hilleke E. Hulshoff Pol and R A Ophoff and R.S. Kahn and Roberto Roiz‐Santiáñez and Benedicto Crespo‐Facorro and Lei Wang and K I Alpert and E G Jönsson and Ralica Dimitrova and C. Bois and Heather C. Whalley and Andrew M. McIntosh and Stephen M. Lawrie and R Hashimoto and Paul M. Thompson and Jessica A. Turner},
  title = {{Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium}},
  booktitle = {Molecular},
  year = {2015},
  doi = {10.1038/mp.2015.63},
}
Figure